Safety of Posaconazole and Sirolimus Coadministration in Allogeneic Hematopoietic Stem Cell Transplants

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 9, 2012, Pages 1462-1465

  Kubiak, David W ^a   Koo, Sophia ^a,b,c   Hammond, Sarah P ^a,b,c   Armand, Philippe ^a,b,c   Baden, Lindsey R ^a,b,c   Antin, Joseph H ^a,b,c   Marty, Francisco M ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Coadministration; Drug interactions; Posaconazole; Sirolimus; Tacrolimus

Indexed keywords

POSACONAZOLE; RAPAMYCIN;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHROCYTE DEFORMABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PROPHYLAXIS; SCHISTOCYTE; SIDE EFFECT; SYSTEMIC MYCOSIS; THROMBOCYTOPENIA;

ADULT; ANTIFUNGAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOSES; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TRIAZOLES;

EID: 84865185424     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.04.015     Document Type: Article

References (16)

1. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001, 72:1924-1929.
2. Ho V.T., Aldridge J., Kim H.T., et al. Comparison of tacrolimus and sirolimus (Tac/Sir) versus tacrolimus, sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:844-850.
3. Sehgal S.N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335-340.
4. Cutler C., Antin J.H. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:471-476.
5. Armand P., Gannamaneni S., Kim H.T., et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008, 26:5767-5774.
6. Cutler C., Li S., Kim H.T., et al. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant 2005, 11:383-388.
7. Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003, 102:1601-1605.
8. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
9. Sattler M., Guengerich F.P., Yun C.H., Christians U., Sewing K.F. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 1992, 20:753-761.
10. Saad A.H., DePestel D.D., Carver P.L. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006, 26:1730-1744.
11. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356:335-347.
12. Gergis U., Markey K., Greene J., et al. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant 2010, 45:662-667.
13. Marty F.M., Lowry C.M., Cutler C.S., et al. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:552-559.
14. Moton A., Ma L., Krishna G., Martinho M., Seiberling M., McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr Med Res Opin 2009, 25:701-707.
15. Nivoix Y., Levêque D., Herbrecht R., et al. The enzymatic basis of drug-drug interactions with systemic triazole antifungals. Clin Pharmacokinet 2008, 47:779-792.
16. Dodds-Ashley E. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 2010, 30:842-854.